^
almost2years
B7-H3 CAR-T for Recurrent or Refractory Glioblastoma (clinicaltrials.gov)
P1/2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2024 --> Aug 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
CD276 (CD276 Molecule)
|
temozolomide • BP102
almost2years
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma (clinicaltrials.gov)
P1, N=12, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial completion date: Jul 2022 --> May 2024 | Trial primary completion date: May 2022 --> Mar 2024
Trial completion date • Trial primary completion date
|
CD276 (CD276 Molecule)
|
temozolomide • BP102